# MRI-Visible Nanovehicle for Efficient siRNA Delivery

Rongrong Jin, Wencheng Zhu, Gan Lin, Gang Liu and Hua Ai

## Abstract 摘要

Visualizing siRNA delivery through medical imaging methods has drawn much attentions in recent gene therapy studies. Among them, iron oxide-based magnetic resonance imaging (MRI) is regarded as one of the most promising imaging modalities for its high spatial resolution as well as deep penetration and real-time properties. In this chapter, a detailed protocol of an amphiphilic superparamagnetic iron oxide (SPIO) nanovehicle-based siRNA delivery is described, mainly focusing on SPIO/siRNA complexes formation and characterization, in vitro and in vivo siRNA delivery, MRI study of the delivery and transfection efficiency evaluation.

<span style=color:blue>在最近的基因治疗研究中，使用医学成像方法来可视化siRNA的递送引起了广泛关注。其中，基于氧化铁的磁共振成像（MRI）因其高空间分辨率、深层穿透性和实时成像能力，被认为是最具前景的成像方式之一。本章详细介绍了一种基于两亲性超顺磁氧化铁（SPIO）纳米载体的siRNA递送方案，主要集中于SPIO/siRNA复合物的形成与表征、siRNA的体内外递送、MRI成像研究及转染效率的评价。</span>

## 1 Introduction 引言

Small interfering RNAs (siRNA) are short molecules of 19–25 nucleotides that can trigger specific gene silencing by unwinding the siRNA duplex when binding to the RNA-induced silencing complex (RISC), thus mediate the cleavage and destruction of a target messenger RNA (mRNA) . It is well established that siRNAs are one of the most important biopharmaceuticals but showing slow progression. To date, two siRNA-based therapeutics have been approved by the US Food and Drug Administration (FDA): those are Patisiran and Givosiran (Alnylam Pharmaceuticals) for treatment of hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, respectively; 33 other siRNA-based therapeutics (http://www.clinicaltrials.gov) have entered clinical trials for treatment of several other refractory diseases including tumors, virus infection, ocular lesions, pachyonychia congenita, hypercholesterolemia, liver fibrosis, hypertrophic scar, delayed graft function, hyperoxaluria, etc. Of note, most of siRNA therapeutics require highly efficient delivery systems which is nowadays the biggest obstacle for developing siRNA therapeutics as a powerful new treatment paradigm. In recent years, carefully designed nanoparticles are developed for siRNA delivery instead of traditionally high-risk viral vectors. However, there are still several challenges presented to siRNA delivery in vivo such as satisfied blood half-life, favorable pathologic tissue target, efficient transfer across the cell membrane, and adequate tissue bioavailability, as well as stability of siRNA. The improvement of these requirements would be greatly accelerated by noninvasive and real-time evaluation methods such as medical imaging tools. Iron oxide nanoparticles based MRI has several advantages over other imaging modalities, including deep tissue penetration, high spatial and temporal resolution, excellent soft tissue contrast, as well as non-radiative compared with *CT* and *SPECT*/*PET* scanning. In our previous studies, low molecular-weight (2 kDa) amphiphilic alkylated polyethylenimine (Alkyl-PEI) wrapped SPIO nanoparticles (Alkyl-PEI/SPIO) were fabricated, showing improved *T*<sub>*2*</sub> relaxivity and good bio-safety. Their siRNA delivery efficiency toward breast cancer cells were also examined both in vitro and in vivo, suggesting a promising nanovehicle for simultaneous noninvasive imaging and delivery of siRNAs.

<span style=color:blue>小干扰RNA（siRNA）是一种由19-25个核苷酸组成的小分子，通过与RNA诱导沉默复合物（RISC）结合并解链来实现特异性基因沉默，从而介导特定信使RNA（mRNA）的切割和降解。虽然siRNA已被确认为重要的生物制药分子，但其研发进展较慢。目前，美国食品药品监督管理局（FDA）已批准了两种siRNA药物，即用于遗传性甲状腺素转运蛋白相关淀粉样变性治疗的Patisiran和用于急性肝性卟啉病的Givosiran（由Alnylam公司研发）；此外，另有33种siRNA药物（http://www.clinicaltrials.gov）已进入临床试验，适应症涵盖肿瘤、病毒感染、眼部疾病、先天性甲床肥厚病、高胆固醇血症、肝纤维化、瘢痕增生、移植物延迟功能、草酸盐尿症等多种难治性疾病。值得关注的是，大多数siRNA药物需要高度有效的递送系统，这已成为其开发为一种新型强效治疗手段的最大瓶颈。近年来，研究者们设计了多种纳米颗粒以替代传统的高风险病毒载体用于siRNA递送。然而，siRNA的体内递送仍面临多重挑战，包括延长血液半衰期、有效靶向病变组织、跨细胞膜高效转运、组织内足够的生物利用度以及提高siRNA稳定性等。借助医学成像等无创、实时的评估技术，可显著加速这些要求的改进。与其他成像方式相比，基于氧化铁纳米颗粒的磁共振成像（MRI）具有多项优势，如深层组织穿透、高空间与时间分辨率、优良的软组织对比度，同时与*CT*、*SPECT*/*PET*相比无辐射风险。在我们之前的研究中，制备了由低分子量（2 kDa）烷基化聚乙烯亚胺（Alkyl-PEI）包裹的超顺磁性氧化铁（SPIO）纳米颗粒（Alkyl-PEI/SPIO），显示出增强的*T*<sub>*2*</sub>弛豫率和良好的生物安全性。在体内外实验中，我们评估了其对乳腺癌细胞的siRNA递送效果，结果显示其有望成为一种集成无创成像和siRNA递送的潜在纳米载体。</span>

This chapter will provide a detailed protocol for Alkyl-PEI/SPIO-siRNA complexes formation and characterization, transfection of siRNA by the complexes, evaluation of cellular uptake as well as transfection efficiency and detection of the labeled cells under a clinical MRI scanner.

<span style=color:blue>本章将详细介绍Alkyl-PEI/SPIO-siRNA复合物的制备与表征方法、复合物的siRNA递送、细胞摄取与转染效率评估及在临床MRI下标记细胞检测的完整实验流程。</span>

## 2 Materials 材料

### 2.1 Reagents 试剂

1. Materials for Alkyl-PEI/SPIO complexes fabrication: 1-iodohexane, 1,2-hexadedecanediol, polyethylenimine (PEI, branched, Mw 2 kDa), Fe(acc)3, oleic acid, oleylamine, benzyl ether, absolute ethanol, hexane, NaOH, chloroform, and fluorescein isothiocyanate (FITC).<span style=color:blue>Alkyl-PEI/SPIO复合物的材料包括：1-碘己烷、1,2-十六烷二醇、聚乙烯亚胺（PEI，支链型，分子量2 kDa）、三乙酰丙酮铁、油酸、油胺、苄醚、无水乙醇、正己烷、氢氧化钠、氯仿和异硫氰酸荧光素（FITC）。</span>
2. Cell culture medium: Culture 4T1-fluc and MCF-7/ADR cell lines in high glucose DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/mL streptomycin and 100 μg/mL penicillin). In addition, add 1 μg/mL doxorubicin into the culture medium of MCF-7/ADR cells for their drug resistance maintenance.<span style=color:blue>细胞培养基的配制：用高葡萄糖DMEM培养4T1-fluc和MCF-7/ADR细胞系，添加10%胎牛血清（FBS）和抗生素（链霉素100 U/mL，青霉素100 μg/mL）。另外，为维持MCF-7/ADR细胞的耐药性，在培养基中添加1 μg/mL的阿霉素。</span>
3. RNAase-free solution: 20 mM HEPES (pH 7.4), 5% glucose in DEPC water.<span style=color:blue>无RNA酶溶液：在DEPC水中配制的20 mM HEPES（pH 7.4）和5%葡萄糖。</span>
4. Tris-acetate running buffer: 40 mM Tris-acetate, 1 mM EDTA, pH 8.3.<span style=color:blue>Tris-乙酸运行缓冲液：40 mM Tris-乙酸、1 mM EDTA，pH值为8.3。</span>
5. Heparin solution: 10 μg/mL heparin sodium in HEPES buffer (20 mM, pH 7.4).<span style=color:blue>肝素溶液：HEPES缓冲液（20 mM，pH 7.4）中含10 μg/mL肝素钠。</span>
6. 4% Paraformaldehyde (PFA): 4% paraformaldehyde in PBS (w/v) solution.<span style=color:blue>4%多聚甲醛（PFA）溶液：在PBS（w/v）溶液中配制4%多聚甲醛。</span>
7. DAPI staining solution: 10 mM DAPI in deionized water.<span style=color:blue>DAPI染色液：在去离子水中配制10 mM DAPI。</span>
8. CCK-8 work solution: 10% CCk-8 stock solution in FBS-free high glucose DMEM medium.<span style=color:blue>CCK-8工作溶液：无血清高葡萄糖DMEM培养基中含10% CCK-8储备溶液。</span>
9. 2% Agarose gel: 2% agarose in tris-acetate running buffer (w/v).<span style=color:blue>2%琼脂糖凝胶：在Tris-乙酸运行缓冲液（w/v）中配制的2%琼脂糖。</span>
10. Ethidium bromide.<span style=color:blue>溴化乙锭。</span>
11. G418 antibiotic select solution: 1 mg/mL in water.<span style=color:blue>G418抗生素选择性溶液：1 mg/mL溶于水中。</span>
12. d-Luciferin substrate: 15 mg/mL in PBS.<span style=color:blue>d-荧光素底物：在PBS中配制的15 mg/mL溶液。</span>
13. Lipofectamine 2000.<span style=color:blue>Lipofectamine 2000转染试剂。</span>
14. 5% Nonfat milk: dissolve nonfat milk powder in TBST solution (5%, w/v).<span style=color:blue>5%脱脂奶粉：将脱脂奶粉溶解在TBST溶液中，浓度为5%（w/v）。</span>
15. Antibodies (P-gp primary antibody, Abcam, ab3366; β-actin, Abcam, ab8226; HRP conjugated secondary antibody, Santa Crus, sc-2005; Cy5 conjugated secondary antibody, ThermoFisher, A10524).<span style=color:blue>抗体：P-gp一抗（Abcam, ab3366）、β-肌动蛋白（Abcam, ab8226）、HRP偶联二抗（Santa Cruz, sc-2005）、Cy5偶联二抗（ThermoFisher, A10524）。</span>
16. Matrigel.<span style=color:blue>Matrigel基质胶。</span>
17. Female athymic nude mice (6–8 week-old).<span style=color:blue>雌性无胸腺裸鼠，年龄6-8周。</span>
18. P-gp siRNA sequence: sense strand: 5′-GAAACCAACUGUCAGUGUAdTdT-3′; antisense strand: 5′-UACACUGACAGUUGGUUUCdTdT-3′. Fluc siRNA sequence: sense 5′-UUGUUUUGGAGCGAAAdTdT-3′; antisense strand: 5′-UUUCCUUCCAAAACAAdTdT-3′. Negative control siRNA sequence: sense strand: 5′-AGUUCAACGACCAGUAGUCdTdT-3′; antisense strand: 5′-GACUACUGGUCGUUGAACUdTdT-3′.<span style=color:blue>P-gp siRNA序列：正义链5′-GAAACCAACUGUCAGUGUAdTdT-3′；反义链5′-UACACUGACAGUUGGUUUCdTdT-3′。Fluc siRNA序列：正义链5′-UUGUUUUGGAGCGAAAdTdT-3′；反义链5′-UUUCCUUCCAAAACAAdTdT-3′。阴性对照siRNA序列：正义链5′-AGUUCAACGACCAGUAGUCdTdT-3′；反义链5′-GACUACUGGUCGUUGAACUdTdT-3′。</span>
19. RIPA buffer: 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% Nonodet-P40, 1% Sodium deoxycholate, 0.1% SDS.<span style=color:blue>RIPA裂解缓冲液：50 mM Tris–HCl（pH 8.0）、150 mM NaCl、1% Nonidet-P40、1%去氧胆酸钠、0.1% SDS。</span>
20. TBST solution: 10 mM Tris–HCl (pH 8.0), 150 mM NaCl, 20% Tween 20 (v/v).<span style=color:blue>TBST溶液：10 mM Tris–HCl（pH 8.0）、150 mM NaCl和20%吐温20（v/v）。</span>
21. 5× SDS loading buffer: 250 mM Tris–HCl (pH 6.8), 10% SDS (w/v), 0.5% Bromophenol Blue (w/v), 50% Glycerol (w/v), 5% β-mercaptoethanol (w/v).<span style=color:blue>5× SDS上样缓冲液：250 mM Tris–HCl（pH 6.8）、10% SDS（w/v）、0.5%溴酚蓝（w/v）、50%甘油（w/v）和5% β-巯基乙醇（w/v）。</span>
22. Chemiluminescent HRP substrates.<span style=color:blue>化学发光HRP底物。</span>

### 2.2 Equipment 设备

1. Rotary evaporator (N-1300D-W, EYELA). <span style=color:blue>EYELA的N-1300D-W型旋转蒸发仪。</span>
2. Dialysis bag (VISKASE).<span style=color:blue>VISKASE品牌的透析袋。</span>
3. NMR spectrometer (AVANCE II-600 MHz, Brucker).<span style=color:blue>布鲁克公司生产的AVANCE II-600 MHz核磁共振波谱仪。</span>
4. Probe sonicator (VCX130; Sonic & Materials Inc.).<span style=color:blue>Sonic & Materials公司的VCX130探头式超声波处理仪。</span>
5. Thermo analysis instrument (TGI, NETZSCH).<span style=color:blue>耐驰的TGI热分析仪。</span>
6. Atomic Force Microscopy (AFM, MFP3D-BIO, Asylum Research).<span style=color:blue>Asylum Research的MFP3D-BIO原子力显微镜（AFM）。</span>
7. Zetasizer Nano ZS (Malvern Instruments, Worcestershire).<span style=color:blue>马尔文仪器公司的Zetasizer Nano ZS粒度分析仪。</span>
8. Transmission electron microscopy (TEM, JM-1011, JEOL).<span style=color:blue>JEOL公司JM-1011型号的透射电子显微镜（TEM）。</span>
9. Horizontal electrophoresis apparatus (Sub-cell GT Cell 170-4482, Bio-Rad).<span style=color:blue>Bio-Rad的Sub-cell GT Cell 170-4482水平电泳系统。</span>
10. Western blot apparatus (Mini-PROTEAN® Tetra 165-8002, Bio-Rad).<span style=color:blue>Bio-Rad的Mini-PROTEAN® Tetra 165-8002蛋白质印迹系统。</span>
11. Molecular Imager ChemiDoc XRS+ (Bio-Rad, 170-8071).<span style=color:blue>Bio-Rad的ChemiDoc XRS+分子成像系统（型号170-8071）。</span>
12. Confocal laser scanning microscopy (CLSM, Leica Microsystems, TCS SP4).<span style=color:blue>徕卡显微系统的TCS SP4型共聚焦激光扫描显微镜（CLSM）。</span>
13. Xenogen IVIS-100 system (Caliper life science).<span style=color:blue>Caliper Life Sciences的Xenogen IVIS-100活体成像系统。</span>
14. MRI 3.0 T scanner (Achieva, Philips).<span style=color:blue>飞利浦的Achieva 3.0 T磁共振成像（MRI）扫描仪。</span>

## 3 Methods 方法

### 3.1 Alkyl-PEI/SPIO Complexes Fabrication 烷基化PEI/SPIO复合物的制备方法

#### 3.1.1 *N*-Alkyl-PEI Synthesis *N*-烷基化PEI的合成过程

1. Add 1 mmol 1-Iodododecane to dry PEI2K (0.25 mM) followed by dissolving them in absolute ethanol (10 mL) in a round-bottom flask (50 mL).<span style=color:blue>将1 mmol的1-碘十二烷加入到0.25 mM的干燥PEI2K中，再用10 mL无水乙醇溶解，反应器选用50 mL的圆底烧瓶。</span>
2. Put the flask into liquid nitrogen to convert the solution into solid and then heat it to 60 °C for 6 h under an argon atmosphere.<span style=color:blue>将烧瓶置于液氮环境中使溶液冷却成固态，然后在氩气气氛下加热至60°C，反应6小时。</span>
3. Use a rotary evaporation to remove the ethanol overnight after cooling the solution to room temperature.<span style=color:blue>溶液冷却到室温后，用旋转蒸发器除去乙醇，操作过夜。</span>
4. Dissolve the crude product in water followed by reacting with 11 mol% of NaOH and then dialyze the mixture in a dialysis bag (molecular mass cutoff, 1 kDa) against gradient EtOH/H<sub>2</sub>O solution at room temperature for purification.<span style=color:blue>将粗产物溶解于水中，加入11 mol%的NaOH溶液进行反应，然后将混合物放入分子量截留1 kDa的透析袋，在梯度EtOH/H<sub>2</sub>O溶液中于室温进行透析纯化。</span>
5. Finally, collect the pure product by freeze-drying and characterize it with <sup>1</sup>H NMR (CDCl<sub>3</sub>).<span style=color:blue>最终，将纯化产物通过冷冻干燥收集，并用<sup>1</sup>H核磁共振 (CDCl<sub>3</sub>) 进行表征。</span>

#### 3.1.2 Superparamagnetic Iron Oxide Nanoparticles Synthesis 超顺磁性氧化铁纳米颗粒的合成方法

1. Mix 1 mmol Fe(acc)<sub>3</sub> with 5 mmol 1,2-hexadecanediol, 3 mmol oleic acid and 3 mmol oleylamine in 10 mL benzyl ether under a nitrogen atmosphere.<span style=color:blue>在氮气环境下，将1 mmol的Fe(acc)<sub>3</sub>与5 mmol 1,2-十六烷二醇、3 mmol油酸和3 mmol油胺混合于10 mL苄醚溶液中。</span>

2. Heat the mixture to reflux (300 °C) for 1 h.<span style=color:blue>将该混合物加热至300°C回流反应1小时。</span>

3. Use ethanol to yield a dark-brown precipitate from the solution after cooling to room temperature.<span style=color:blue>冷却至室温后，加入乙醇以析出深褐色沉淀物。</span>

4. Redisperse the product obtained from above step in hexane with oleic acid and oleylamine.<span style=color:blue>将得到的沉淀产物重新分散在含油酸和油胺的正己烷溶液中。</span>

5. Use ethanol to reprecipitate 6 nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles.<span style=color:blue>用乙醇再次沉淀，得到6 nm的Fe<sub>3</sub>O<sub>4</sub>纳米颗粒。</span>

6. Use the 6 nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles as seeds to synthesize 12 nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles.<span style=color:blue>以6 nm Fe<sub>3</sub>O<sub>4纳米颗粒为种子进行二次生长，制备12 nm的Fe3O4纳米颗粒。</span>

   (a) Orderly mix 1 mmol Fe(acc)<sub>3</sub>with 5 mmol 1,2-hexadecanediol, 10 mL benzyl ether, 1 mmol oleic acid, 3 mmol oleylamine, and 41 mg 6 nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles dissolved in hexane.<span style=color:blue>将1 mmol Fe(acc)<sub>3</sub>、5 mmol 1,2-十六烷二醇、10 mL苄醚、1 mmol油酸、3 mmol油胺和41 mg的6 nm Fe<sub>3</sub>O<sub>4</sub>纳米颗粒（溶于正己烷）依次混合。</span>

   (b) Heat the mixture to 100 °C for 30 min to remove hexane.<span style=color:blue>将混合物加热至100°C保持30分钟，去除正己烷。</span>

   (c) Heat the mixture to reflux for 30 min at 300 °C. After cooling to room temperature, use ethanol to yield a dark-brown precipitate from the solution.<span style=color:blue>将混合物加热至300°C并保持回流30分钟，冷却至室温后用乙醇沉淀，得到深褐色沉淀物。</span>

   (d) Redisperse the product in hexane with oleic acid and oleylamine followed with reprecipitation by ethanol to give 12 nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles.<span style=color:blue>将产物重新分散于含油酸和油胺的正己烷溶液中，再用乙醇沉淀得到12 nm Fe<sub>3</sub>O<sub>4</sub>纳米颗粒。</span>

7. Characterize the SPIO nanoparticles by DLS and TEM.<span style=color:blue>使用动态光散射（DLS）和透射电子显微镜（TEM）对SPIO纳米颗粒进行表征分析。</span>

#### 3.1.3 Alkyl-PEI/SPIO Complexes Fabrication 烷基化PEI/SPIO复合物的制备过程

1. Redisperse 5 mg SPIO nanoparticles and 3 mg *N*-alkyl-PEI2K in 1 mL chloroform.<span style=color:blue>将5 mg的SPIO纳米颗粒和3 mg的*N*-烷基化PEI2K溶于1 mL氯仿中。</span>
2. Dropwise add above yield solution to 10 mL water under probe sonication at room temperature.<span style=color:blue>逐滴将上述溶液加入10 mL水中，在室温下使用探头超声协助分散。</span>
3. Mix the solution by shaking for 24 h and remove residual chloroform by rotary evaporation.<span style=color:blue>混合溶液，震荡24小时，随后通过旋转蒸发去除残余氯仿。</span>
4. Detect composition of Alkyl-PEI/SPIO-siRNA via thermogravimetry analysis (TGA) at a heating rate of 10 °C/min from 35 to 1000 °C under a nitrogen atmosphere.<span style=color:blue>通过热重分析 (TGA) 测定烷基化PEI/SPIO-siRNA复合物的组成，分析温度范围为35至1000°C，升温速率10 °C/min，氮气气氛下进行。</span>
5. Characterize the size and morphology of Alkyl-PEI/SPIO complexes through DLS, zeta potential, AFM, and TEM.<span style=color:blue>采用动态光散射 (DLS)、zeta电位分析、原子力显微镜 (AFM) 和透射电子显微镜 (TEM) 表征复合物的尺寸及形态。</span>

#### 3.1.4 Label Alkyl-PEI/SPIO Complexes with FITC 烷基化PEI/SPIO复合物的FITC标记方法

1. Redisperse 5 mg SPIO nanoparticles and 3 mg *N*-alkyl-PEI2K in 1 mL chloroform.<span style=color:blue>将5 mg的SPIO纳米颗粒和3 mg的*N*-烷基化PEI2K溶于1 mL氯仿中。</span>
2. Dropwise add above yield solution to 10 mL water with probe sonication at room temperature.<span style=color:blue>逐滴将上述溶液加入10 mL水中，使用探头超声进行分散。</span>
3. Mix the solution by shaking for 24 h and remove residual chloroform by rotary evaporation.<span style=color:blue>混合并震荡溶液24小时，使用旋转蒸发器去除残余氯仿。</span>
4. Dissolve FITC (200 μg) in 100 μL DMSO and then add the solution dropwise to the Alkyl-PEI/SPIO complexes yield above.<span style=color:blue>将200 μg FITC溶解在100 μL DMSO中，并逐滴加入制备好的烷基化PEI/SPIO复合物溶液中。</span>
5. Mix the solution by magnetic stirring overnight and remove the residual FITC and DMSO by dialysis as described above.<span style=color:blue>磁力搅拌溶液过夜，通过透析去除残余的FITC和DMSO，操作方法同前。</span>
6. Finally, collect the pure product by freeze-drying and characterize it with <sup>1</sup>H NMR (CDCl<sub>3</sub>).<span style=color:blue>最终，冷冻干燥收集纯化的产物，并使用<sup>1</sup>H NMR (CDCl<sub>3</sub>) 进行表征分析。</span>

### 3.2 Alkyl-PEI/SPIO-siRNA Complex Formation and Characterization (see Note **1**) 烷基化PEI/SPIO-siRNA复合物的制备与表征

1. Gently added the required amount of siRNA solution to Alkyl-PEI/SPIO dispersions in RNAase-free solution with different N/P ratios (i.e., N/P ratios are set as 0, 1, 5, 10, 20, 40) (*see* **Note** **2** ).<span style=color:blue>在含RNA酶抑制剂的溶液中，将所需的siRNA溶液缓慢加入不同N/P比（设定为0、1、5、10、20、40）的烷基化PEI/SPIO分散液中（*见* 注释2）。</span>
2. Incubate the prepared mixture at room temperature for 15–20 min to allow for the condensation of siRNA by amines on Alkyl-PEI/SPIO.<span style=color:blue>室温下将混合物孵育15–20分钟，以便通过烷基化PEI/SPIO的胺基对siRNA进行凝聚。</span>
3. Characterize the particle size and zeta potential of nano complexes by dynamic light scattering (DLS); observe particle morphology by transmission electron microscopy (TEM).<span style=color:blue>使用动态光散射（DLS）检测纳米复合物的粒径和zeta电位，并通过透射电子显微镜（TEM）观察颗粒的形态。</span>
4. Use Gel retardation assay to evaluate the siRNA compaction efficacy in complexes at different N/P ratios. Load All samples containing 200 ng siRNA onto 2% agarose gel (w/v) with 0.5 μg/mL ethidium bromide in tris-acetate running buffer for electrophoresis (100 V, 15 min). Image siRNA bands by the Molecular Imager ChemiDoc XRS+. Express binding capacity by the threshold N/P ratio, above which siRNA are completely retarded in the pores and below which unbound siRNA migrated quickly through the gel matrix (Fig. 1a).<span style=color:blue>使用凝胶阻滞实验评估siRNA在不同N/P比下的紧密结合效果。将所有含200 ng siRNA的样品加载到2%琼脂糖凝胶中（含0.5 μg/mL溴化乙锭）并在tris-醋酸缓冲液中电泳（100 V，15分钟），通过Molecular Imager ChemiDoc XRS+对条带进行成像。结合能力通过阈值N/P比表示，高于该比值siRNA完全被阻滞在孔中，低于该比值时未结合的siRNA会快速通过凝胶（图1a）。</span>
5. Use heparin decomplexation assay to mimic the siRNA release behavior under biological environment in vitro. Mix Alkyl-PEI/SPIO and siRNA (200 ng) at totally condensation N/P ratio (20:1) and incubate them at room temperature for 15 min. Then add varied amounts of heparin (heparin/siRNA weight ratio: 0, 100, 25, 10, 2) for another 15 min incubation at room temperature. Thereafter subject the mixtures to the gel electrophoresis analysis as described above. Reflect the release efficacy as well as binding capacity by the amount of added heparin (Fig. 1b).<span style=color:blue>采用肝素解复合实验模拟体外生物环境下的siRNA释放。将烷基化PEI/SPIO与siRNA（200 ng）按完全凝聚的N/P比（20:1）混合，室温孵育15分钟。然后加入不同量的肝素（肝素/siRNA重量比为0、100、25、10、2），再在室温下孵育15分钟，并进行凝胶电泳分析，以反映释放效率和结合能力（图1b）。</span>
6. For evaluation of the stability of complexes in serum, firstly mix Alkyl-PEI/SPIO and siRNA (200 ng) at ratio of N/P = 20 followed by incubation at room temperature for 15 min as described above. Then add an equal volume of FBS and incubate the mixtures at 37 °C for predetermined periods (0, 3, 6, 12, 24 h). After that, treat samples with heparin (10 μg/mL) for 15 min to release siRNA . Subject the resulting mixtures to the gel electrophoresis analysis as described above (Fig. 1d). Here recommend naked siRNA as negative control which can be degraded without nanovehicle protection (Fig. 1c).<span style=color:blue>为评估复合物在血清中的稳定性，首先将烷基化PEI/SPIO与siRNA（200 ng）按N/P=20的比率混合，室温孵育15分钟。随后加入等体积的FBS，在37°C孵育指定时间（0、3、6、12、24小时），之后加入肝素（10 μg/mL）孵育15分钟以释放siRNA，最终通过凝胶电泳分析样品（图1d）。建议使用裸siRNA作为阴性对照，因为其在未受纳米载体保护的情况下会被降解（图1c）。</span>

![../images/485053_1_En_13_Chapter/485053_1_En_13_Fig1_HTML.png](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_13_Fig1_HTML.png)

**Fig. 1** Agarose gel electrophoresis analysis of Alkyl-PEI/SPIO-siRNA complexes. (**a**) Gel retardation assay of Alkyl-PEI/SPIO-siRNA complexes with varied N/P ratios. (**b**) Release behavior of siRNA in Alkyl-PEI/SPIO-siRNA complexes (N/P = 20) with the addition of heparin at various concentrations. (**c**) Stability of siRNA in 50% serum when complexed with Alkyl-PEI/SPIO at N/P ratio of 20 for distinct incubation times. (**d**) Stability of naked siRNA in 50% serum for distinct incubation times.

### 3.3 Cellular Uptake of Alkyl-PEI/SPIO-siRNA Complexes 烷基化PEI/SPIO-siRNA复合物的细胞摄取实验

1. Seed MCF-7/ADR or 4T1-fluc cells into 35 mm glass-bottom dishes at a density of 1–2 × 10<sup>5</sup> following 24 h adhesion. <span style=color:blue>将MCF-7/ADR或4T1-fluc细胞接种在35 mm玻片培养皿中，密度为1–2 × 10<sup>5</sup>，并培养24小时以促进细胞贴壁。</span>
2. Mix siRNA (50 nM, 100 pmol) with appropriate FITC labeled Alkyl-PEI/SPIO at N/P ratio of 20. After 15–20 min incubation, add the mixtures into cells with freshly changed culture medium for following 12 h incubation.<span style=color:blue>将50 nM（100 pmol）的siRNA与标记有FITC的烷基化PEI/SPIO按N/P比为20混合，孵育15–20分钟后，将混合物加入更换了新鲜培养基的细胞中，继续孵育12小时。</span>
3. Then remove the medium and wash cells with PBS for three times.<span style=color:blue>移除培养基后，用PBS冲洗细胞三次。</span>
4. Fix cells with 4% PFA for 10 min at room temperature and wash cells with PBS for three times.<span style=color:blue>使用4% PFA在室温下固定细胞10分钟，然后用PBS冲洗细胞三次。</span>
5. Counterstain nuclei with DAPI for 3–5 min at room temperature followed by washing with PBS for three times. <span style=color:blue>使用DAPI在室温下对细胞核进行3–5分钟的染色处理，再用PBS冲洗三次。</span>
6. Use CLSM for assessing the intracellular siRNA trafficking (Fig. 2).<span style=color:blue>通过共聚焦激光扫描显微镜（CLSM）分析细胞内siRNA的运输路径（图2）。</span>

![485053_1_En_13_Fig2_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_13_Fig2_HTML.png)

**Fig. 2** Cellular uptake of Alkyl-PEI/SPIO-siRNA complexes by MCF-7/ADR cells. Confocal microscopic images of MCF-7/ADR cells after transfection with siRNA complexed with FITC labeled Alkyl-PEI/SPIO. The nuclei were stained with DAPI. Scale bars: 25 μm. 

### 3.4 Cell Transfection and Cytotoxicity of Alkyl-PEI/SPIO-siRNA Complexes 烷基化PEI/SPIO-siRNA复合物的细胞转染与毒性评估

1. Seed MCF-7/ADR or 4T1-fluc cells into 6-well plate at a density of 1–2 × 105/well with following 24 h adhesion (*see* **Note** **3**).<span style=color:blue>将MCF-7/ADR或4T1-fluc细胞按1–2 × 10^5/孔的密度接种于6孔板中，培养24小时使细胞贴壁（详见注释3）。</span>
2. Mix siRNA (50 nM, 100 pmol/well) with appropriate Alkyl-PEI/SPIO at N/P ratio of 20. After 15–20 min incubation, add the mixtures into the cells with freshly changed culture medium for following 12 h incubation.<span style=color:blue>将50 nM（100 pmol/孔）的siRNA与烷基化PEI/SPIO按N/P比20混合，孵育15–20分钟后，将混合物加入更换了新鲜培养基的细胞中，继续孵育12小时。</span>
3. Then replace the medium with fresh one followed by continuously culture for 48 h.<span style=color:blue>随后更换培养基并继续培养48小时。</span>
4. Add CCK-8 work solution after removing the culture medium for cytotoxicity assay and measure the absorption value at 450 nm after 2–4 h incubation.<span style=color:blue>在移除培养基后添加CCK-8工作液，孵育2–4小时后在450 nm处测定吸光值，以评估细胞毒性。</span>

### 3.5 Transfection Efficiency Evaluation

#### 3.5.1 Luciferase Activity Assay

1. Establish luciferase stably expressed 4T1 cells (4T1-fluc). Seed 4T1 cells into 6-well plate at a density of 1–2 × 10<sup>5</sup>/well and transfected cells with pcDNA3.1 vector expressing cytomegalovirus-firefly luciferase (fluc) using Lipofectamine 2000 according to the standard reagent protocol. After 48 h transfection, transmit cells in one well to a 10-cm culture dish for monoclonal cell group selection. Add 1 mg/mL G418 antibiotic to the culture medium for cell selection and replace it every 2 days. Two weeks later, select several single clones and transfer them into separate wells of a 48-well culture plate. Screen the clones using a Xenogen IVIS-100 system by adding the substrate d-luciferin. Select and scale up the highest fluc activity clones for further study (*see* **Note** **5**).
2. Transfect the selected 4T1-fluc cells with Alkyl-PEI/SPIO-siRNA (fluc siRNA and negative control siRNA) complexes as described above. Prepare Lipofectamine 2000, PEI2k, and Alkyl-PEI2k as comparing groups.
3. Lyse the cells and collect the supernatants followed by adding the substrate d-luciferin for luciferase activity assay as described above (Fig. 3). 

![485053_1_En_13_Fig3_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_13_Fig3_HTML.png)

**Fig. 3** Relative luciferase activity of 4T1-fluc cells after siRNA transfection. 

#### 3.5.2 Western Blot Analysis

1. Transfect P-gp overexpressed MCF-7/ADR cells with Alkyl-PEI/SPIO-siRNA (P—Prepared Lipofectamine 2000 as control group).
2. Lyse cells by RIPA buffer added with protease inhibitor for 15 min at 0 °C following centrifuging at 10,000 × *g* for 15 min.
3. Add 5× SDS loading buffer to the collected supernatants from above step following boiling at 100 °C for 5 min.
4. Then subject the samples to 10% SDS-polyacrylamide gel electrophoresis for 1 h at 100 V.
5. Transfer the protein from the gel to the methanol pretreated PVDF membrane in transfer buffer (1.5 h at 100 V).
6. Split the band of β-actin (45 kDa) and P-gp (130 kDa) and block the membranes for 1 h at RT using 5% nonfat milk.
7. Wash the membranes with TBST for three times followed by incubation with diluted primary antibody (1:1000) in TBST overnight at 4 °C.
8. After washing the membrane with TBST for three times, incubate the membranes with HRP conjugated secondary antibody (1:5000) in TBST at room temperature for 1–2 h.
9. Thoroughly wash the membrane with TBST for four times and capture the images by Molecular Imager ChemiDoc XRS+ after adding chemiluminescent HRP substrates. 

#### 3.5.3 Immunofluorescent Staining (Fig. 4)

1. Transfect P-gp overexpressed MCF-7/ADR cells with Alkyl-PEI/SPIO-siRNA (P-gp siRNA, negative control siRNA) complexes as described above. Prepare Lipofectamine 2000 as control group.
2. Remove culture medium and wash cells with PBS for three times.
3. Fix cells with 4% PFA for 10 min at room temperature followed by washing with PBS for three times.
4. Incubate cells with P-gp primary antibody (1:200) overnight at 4 °C.
5. After washing with PBS for three times, stain cells with Cy5 conjugated secondary antibody (1:5000) for 1 h at room temperature.
6. Counterstain the fixed cells with DAPI after washing with PBS for three times. Observe and capture images by using Florescent microscope.

![485053_1_En_13_Fig4_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_13_Fig4_HTML.png)

**Fig. 4** Immunofluorescence staining for P-gp in MCF-7/ADR cells. Fluorescent microscopic images of MCF-7/ADR cells after transfection with P-gp siRNA complexed with Alkyl-PEI/SPIO. The nuclei were stained with DAPI. Scale bars: 50 μm. Untreated cells are served as control group.

### 3.6 MRI Study of Transfected Cells (Fig. 5)

1. Seed 4T1-fluc into 6-well plate followed by transfection with Alkyl-PEI/SPIO-siRNA complexes as above described.
2. At the end of transfection, wash cells with PBS and then digest them with 0.25% trypsin, which are then collected by centrifuging at 200 × *g* for 5 min.
3. Resuspend cell pellets in 4% PFA to fix at 4 °C for 30 min.
4. Then centrifuge cells at 200 × *g* for 5 min and wash the cells with PBS for three times. Disperse cells in a final concentration of 1% gelatin phantom (200 μL) crosslinked with glutaraldehyde in microcentrifuge tubes. Prepare the gelatin phantoms with untreated cells as negative control.
5. Perform MR imaging of the phantoms at 3.0 T MRI scanner using a clinical head coil. Acquire *T*<sub>*2*</sub>-weighted fast spin echo (TSE) images with the following parameters: repetition time (TR) = 2300 ms, echo time (TE) = 104 ms, slice thickness = 1.0 mm, no gap, field of view (FOV) = 70 × 70 mm, flip angle = 90°, number of signal averaged (NSA) = 8.

![485053_1_En_13_Fig5_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_13_Fig5_HTML.png)

**Fig. 5** (**a**) *T* <sub>*2*</sub>-weighted magnetic resonance images of agarose gel phantoms containing the fluc-4T1 cells treated with Alkyl-PEI/SPIO-siRNA complexes; (**b**) negative correlation between the *T* <sub>*2*</sub>contrast and the N/P ratios of the Alkyl-PEI/SPIO-siRNA complexes (Probability value, *p* < 0.05). 

### 3.7 siRNA Delivery by Alkyl-PEI/SPIO Nanovehicle In Vivo

#### 3.7.1 Luciferase Activity Assay

1. Subcutaneously inject 1 × 10<sup>6 </sup>4T1-fluc cells suspended in serum-free medium into posterior flank of female athymic nude mice (6–8 weeks old, five per group).
2. Intratumorally inject 250 pmol fluc siRNA wrapped with Alkyl-PEI/SPIO (N/P = 20) every other day for three times while the tumor diameter reached about 4–6 mm. Prepare same volume of PBS, free siRNA, and Alkyl-PEI/SPIO as control group (*see* **Note** **5**).
3. After 2 days of each injection, intraperitoneally administrate mice with 50 mg/kg d-luciferin potassium salt and then anesthetize them by 2% isoflurane in O<sub>2</sub>.
4. Measure bioluminescence by a Xenogen IVIS-100 system between 5 and 20 min after the d-luciferin administration (Fig. 6).

![485053_1_En_13_Fig6_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_13_Fig6_HTML.png)

**Fig. 6** Gene-silencing effect by Alkyl-PEI/SPIO-siRNA complexes in vivo. (**A**) In vivo optical images and (**B**) quantitative analysis of fluc-expressing tumors after intratumoral injection of Alkyl-PEI/SPIO-siRNA complexes.

#### 3.7.2 Tissue Western Blot Assay

1. Orthotopically inject 1 × 10<sup>6</sup> MCF-7/ADR cells suspended in 50 μL Matrigel into mammary fat pad of female athymic nude mice (6–8 weeks old, five per group).
2. Intratumorally inject 250 pmol of P-gp-siRNA wrapped with Alkyl-PEI/SPIO (N/P = 20) every 2 days for four times while the tumor diameter reached about 4–6 mm. Prepare same volume of PBS, free siRNA, as well as Lipofectamine wrapped P-gp-siRNA as the control group (*see* **Note** **5**). 
3. After 2 days of last injection , extract and ground the tumor tissues in liquid nitrogen after sacrificing the mice.
4. Lyse the tumor tissue power about 0.1 g of each group in 100 μL RIPA buffer added with protein protease inhibitor.
5. After 30 min lysis at 4 °C, collect the supernatants for the western blot analysis by centrifugation of the samples at 10,000 × *g* for 15 min at 4 °C as described above.

## 4 Notes

1. The Alkyl-PEI/SPIO-siRNA complex forming protocol can be employed for multiple siRNA sequences.
2. When forming the Alkyl-PEI/SPIO-siRNA complex for gene transfection, the volume of siRNA solution should be less than or equal to the nanocomposite dispersions.
3. When using Alkyl-PEI/SPIO for other cells siRNA transfection, the seeded cell number is determined by the cell growth rate reaching a confluent of 70–90%.
4. When constructing other luciferase stably expressed cell lines, the dosage and time of antibiotic need to be further screened.
5. When intratumorally inject the agents, about 30 s retention is suggested to prevent the leakage after each injection by using 1 mL syringe with 18 G needle.